Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Patrick Schöffski ,S Richter,L H Lindner,S J Strauss,T Raveloarivahy,T Van Cann,Piotr Rutkowski ,M G Leahy,A Anthoney,M Debiec-Rychter,Winette Ta Van Der Graaf ,M Lia,Raf Sciot ,F Duffaud,S Marréaud,Jean‐Yves Blay ,Laurence Collette ,Silvia Stacchiotti ,P Reichardt,J Sufliarsky,V Grünwald,Agnieszka Woźniak ,Sebastian Bauer

doi:10.1093/annonc/mdx823

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Patrick Schöffski , S Richter + Show 21 more

Open Access

https://doi.org/10.1093/annonc/mdx823

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Feb 1, 2019
Citations: 8	License type: publisher-specific-oa

#Safety Of Crizotinib In Patients #Advanced Clear-cell Sarcoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

Full Text